| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Wednesday, November 8, 2017 Former Roche and Calico vet Hal Barron has become the new CSO and research chief at GlaxoSmithKline amid a shake-up from its new CEO Emma Walmsley. |
|
|
Top Stories Of The Week Thursday, November 9, 2017 Eli Lilly has persuaded 2,300 employees to take early retirement as part of a companywide streamlining designed to save $500 million. With those settled, the company says it's "on track to achieve" the 3,500 job cuts it outlined in September, with some facilities closing entirely. Monday, November 6, 2017 Just hours after Roche confirmed that 130 workers will be cut from a California facility by the end of the year, the drugmaker said it will shave 235 jobs from a plant in Europe as it switches up how it handles drug packaging. Tuesday, November 7, 2017 Amgen is laying off 200 people across its R&D organization. The latest victims of the big biotech’s ongoing pursuit of efficiency gains mainly work at its facilities in California. Tuesday, November 7, 2017 Allergan is facing allegations it betrayed shareholder interests by not disclosing details about generic price hikes. Wednesday, November 8, 2017 About a year after QuintilesIMS was born from a megamerger between Quintiles and IMS Health, the contract research giant has decided to turn the page and rebrand as IQVIA, pronounced as “I-Q-via.” Monday, November 6, 2017 The brain cancer glioblastoma is notoriously difficult to treat, largely because the blood-brain barrier prevents many drugs from breaking through and reaching their target. Researchers in the U.K. tested AstraZeneca’s PARP inhibitor Lynparza and found it can penetrate the blood-brain barrier and invade glioblastoma tumors. Monday, November 6, 2017 By focusing on countries where dengue is endemic, Sanofi had hoped to put its vaccine on a quick path to blockbuster sales. But nearly two years later, Dengvaxia has yet to generate its first €100 million. Luckily for the company, its other vaccines are performing far better. Thursday, November 9, 2017 Novartis breast cancer med Kisqali has struggled to gain traction in a field dominated by Pfizer blockbuster Ibrance. So it’s going where Ibrance hasn’t. Monday, November 6, 2017 Medtronic’s Intellis platform grabbed a CE mark for peripheral nerve and spinal cord stimulation. Resources Sponsored by: Veeva Systems Gain a complete, real-time view of quality and streamline operations. Incorporate partners into processes for critical oversight and 30% greater efficiency, and transform cross-functional processes like change control. Presented by: DSM Biomedical Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases. Sponsored by: ePharmaSolutions As clinical trials become more complex, safety document distribution to investigative sites has reached the point that demands a solution. Sponsored by: Ashfield Healthcare December 5, 2017 | 2pm EST / 11am PST | Sponsored By Ashfield Healthcare Join this webinar to learn methods that maintain and build sales momentum despite turnover. Sponsored by: Veeva CROs are leading an industry wide shift to modernize clinical systems and clinical trial processes. |
|
